Mutual of America Capital Management LLC Has $2.36 Million Stake in Roivant Sciences Ltd. $ROIV

Mutual of America Capital Management LLC trimmed its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 3.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 209,363 shares of the company’s stock after selling 7,317 shares during the period. Mutual of America Capital Management LLC’s holdings in Roivant Sciences were worth $2,360,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. CWM LLC increased its holdings in Roivant Sciences by 44.6% during the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after purchasing an additional 920 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Roivant Sciences by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 17,110 shares of the company’s stock valued at $173,000 after buying an additional 1,434 shares during the last quarter. GAMMA Investing LLC boosted its position in Roivant Sciences by 22.9% in the 2nd quarter. GAMMA Investing LLC now owns 7,978 shares of the company’s stock valued at $90,000 after buying an additional 1,485 shares during the last quarter. UMB Bank n.a. boosted its position in Roivant Sciences by 42.0% in the 2nd quarter. UMB Bank n.a. now owns 5,883 shares of the company’s stock valued at $66,000 after buying an additional 1,740 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its position in Roivant Sciences by 94.8% in the 1st quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company’s stock valued at $46,000 after buying an additional 2,233 shares during the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Trading Up 0.6%

ROIV stock opened at $18.22 on Friday. The business’s 50-day moving average price is $14.60 and its two-hundred day moving average price is $12.32. The firm has a market cap of $12.44 billion, a PE ratio of -26.03 and a beta of 1.20. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $18.42.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ROIV. Guggenheim increased their price objective on Roivant Sciences from $15.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, September 18th. JPMorgan Chase & Co. increased their price objective on Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, September 18th. Leerink Partners increased their price objective on Roivant Sciences from $18.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, September 18th. Bank of America increased their price objective on Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a research report on Thursday, September 18th. Finally, HC Wainwright increased their price objective on Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.94.

Insider Activity

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 1,195,000 shares of Roivant Sciences stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $12.50, for a total transaction of $14,937,500.00. Following the transaction, the insider directly owned 36,089,108 shares in the company, valued at approximately $451,113,850. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Eric Venker sold 683,818 shares of Roivant Sciences stock in a transaction dated Friday, September 19th. The stock was sold at an average price of $14.95, for a total value of $10,223,079.10. Following the transaction, the chief executive officer owned 1,969,767 shares in the company, valued at approximately $29,448,016.65. This represents a 25.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,228,958 shares of company stock worth $76,447,638. Corporate insiders own 10.80% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.